Recombinant Human GM-CSF is widely used in medical and research settings to stimulate the production and function of white blood cells, particularly granulocytes and macrophages. It is commonly applied in oncology to support patients undergoing chemotherapy, helping to reduce the risk of infections by accelerating white blood cell recovery after bone marrow suppression. It is also used following bone marrow transplantation to promote engraftment and immune reconstitution.

In clinical immunology, this protein is utilized to treat neutropenia, especially in patients with compromised hematopoietic function. It has been investigated in the treatment of infectious diseases in immunocompromised individuals, enhancing the body’s ability to fight pathogens through improved phagocyte activity.

In research, Recombinant Human GM-CSF is employed to differentiate and mature dendritic cells from precursor cells, making it essential in vaccine development and cancer immunotherapy studies. It is also used in cell culture systems to maintain and expand specific immune cell populations for functional assays.